Patents by Inventor Bernard L. Horecker

Bernard L. Horecker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 4716148
    Abstract: A new biological polypeptide hormone has been isolated from mammalian thymus and has been given the designation prothymosin alpha. This peptide contains approximately 107 to 113 amino acid residues depending on species and is distinguished by having the thymosin alpha.sub.1 sequence at its amino-terminus. Prothymosin alpha appears to represent the native polypeptide from which thymosin alpha.sub.1, thymosin alpha.sub.11 and other fragments are generated during the isolation of thymosin fraction 5. Prothymosin alpha is one of several peptides isolated from the thymic tissue which participate in the regulation, differentiation and function of thymic dependent lymphocytes (T cells). The new peptide appears to be more potent on a weight basis than thymosin alpha.sub.1 in the protection of subject animals against opportunistic infections.
    Type: Grant
    Filed: November 18, 1986
    Date of Patent: December 29, 1987
    Assignee: Hoffman-La Roche Inc.
    Inventor: Bernard L. Horecker
  • Patent number: 4696915
    Abstract: Parathymyosin alpha is a novel peptide isolated from mammalian thymus and contains approximately 105 amino acid residues. It bears a high degree of homology to prothymosin alpha both in sequence and amino acid composition. Parathymosin alpha acts as a blocker or modulator or prothymosin alpha activity.
    Type: Grant
    Filed: November 4, 1985
    Date of Patent: September 29, 1987
    Assignee: Hoffmann-La Roche Inc.
    Inventor: Bernard L. Horecker
  • Patent number: 4659694
    Abstract: A new biological polypeptide hormone has been isolated from mammalian thymus and has been given the designation prothymosin alpha. This peptide contains approximately 107 to 113 amino acid residues depending on species and is distinguished by having the thymosin alpha.sub.1 sequence at its amino-terminus. Prothymosin alpha appears to represent the native polypeptide from which thymosin alpha.sub.1, thymosin alpha.sub.11 and other fragments are generated during the isolation of thymosin fraction 5. Prothymosin alpha is one of several peptides isolated from thymic tissue which participate in the regulation, differentiation and function of thymic dependent lymphocytes (T cells). The new peptide appears to be more potent on a weight basis than thymosin alpha.sub.1 in the protection of subject animals against opportunistic infections.
    Type: Grant
    Filed: August 13, 1984
    Date of Patent: April 21, 1987
    Assignee: Hoffmann-La Roche Inc.
    Inventor: Bernard L. Horecker
  • Patent number: 4614731
    Abstract: A new biologically active polypeptide hormone has been isolated from calf thymosin fraction 5 and has been given the designation thymosin alpha.sub.11. The peptide contains seven additional amino acid residues at the carboxy terminus when compared to thymosin alpha.sub.1. Thymosin alpha.sub.11 is one of several peptides present in thymosin fraction 5 which participate in the regulation, differentiation and function of thymic dependent lymphocytes (T cells). The new peptide is approxomately 16 times as potent in the protection of subject animals against opportunistic infections as thymosin fraction 5 and approximately equal in potency to thymosin alpha.sub.1.
    Type: Grant
    Filed: June 10, 1985
    Date of Patent: September 30, 1986
    Assignee: Hoffmann-La Roche Inc.
    Inventor: Bernard L. Horecker
  • Patent number: 4389343
    Abstract: Novel polypeptides, designated thymosin .beta..sub.8 and thymosin .beta..sub.9, have been isolated from calf thymus and their amino acid sequences established. These peptides are active agents for restoring or stimulating immune function, especially for opportunistic infection.
    Type: Grant
    Filed: December 24, 1981
    Date of Patent: June 21, 1983
    Assignee: Hoffmann-La Roche Inc.
    Inventor: Bernard L. Horecker
  • Patent number: 4388234
    Abstract: A process for isolating selected polypeptides from biological specimens. The process employs a guanidinium salt to treat frozen biological specimens from which selected polypeptides are to be obtained. The process is useful in reducing proteolytic modification of the selected polypeptides.
    Type: Grant
    Filed: December 28, 1981
    Date of Patent: June 14, 1983
    Assignee: Hoffmann-La Roche Inc.
    Inventor: Bernard L. Horecker
  • Patent number: 4374197
    Abstract: A process is described for the preparation of thymosin .alpha..sub.1 from desacetylthymosin .alpha..sub.1 in the presence of an acetylating agent and a biologically active ribosome preparation. Thymosin .alpha..sub.1 is useful in increasing T-cell numbers and normalizing immune function in patients with thymic dependent primary immunodeficiency diseases and in cancer patients who are immunodepressed.
    Type: Grant
    Filed: September 8, 1981
    Date of Patent: February 15, 1983
    Assignee: Hoffmann-La Rocche Inc.
    Inventor: Bernard L. Horecker